Cell line development, process dev, protein production tech

Artes Biotechnology specializes in the development and manufacturing of recombinant proteins using advanced microbial cell line technologies, primarily leveraging yeast and bacteria. Their offerings include comprehensive cell line and process development services, which are crucial for producing high-quality test and preclinical materials. The company utilizes proprietary expression systems, such as Hansenula polymorpha and Escherichia coli, to create stable cell lines capable of producing a variety of recombinant proteins, including antigens, enzymes, and functional proteins. Their innovative platforms also support the development of virus-like particle vaccines, ensuring that products meet regulatory standards set by authorities like the EMA and US-FDA.

The company emphasizes a transparent project design that includes detailed documentation, timelines, and milestones to optimize outcomes and minimize risks in recombinant protein production. Their yeast-based systems are particularly noted for their ability to integrate high copy numbers of expression cassettes, which enhances productivity while maintaining cost-effectiveness. Artes Biotechnology's commitment to quality is reflected in their rigorous processes, which ensure the absence of contaminants and allergens, and their ability to produce proteins with high purity. This positions them as a reliable partner for clients seeking efficient solutions in biopharmaceutical development and manufacturing.

Germany

ARTES Biotechnology is a globally working, well established and reliabletechnology provider for recombinant protein production. They develop microbial cell lines and processes for vaccines, biopharmaceuticals, biosimilars and enzymes and offer ready-to-transfer processes for a wide range of products.

Artes Biotechnology

Company Details